MERCK: GOOD HEALTH Thanks to heavy research spending and a commitment to innovative new products, the health-care industry boasts many of the fittest companies in the S&P 500. An unprecedented eight drugs introduced in 1994 and '95 helped push giant Merck to the top of the sector, while little-known Medtronic has churned out red-hot growth by developing state-of-the-art heart pacemakers. And all benefited from strong stock runups as fears of government-inspired health-care reform subsided.

Updated June 15, 1997 by bwwebmaster
Copyright 1997, by The McGraw-Hill Companies Inc. All rights reserved.
Terms of Use